H19 did not explain azacitidine resistance in leukaemia cells
Long exposure to azacitidine increased the long non-coding RNA H19 in two leukaemia cell models. Yet raising or lowering H19 did not change cell proliferation, cell death or response to the drug. The negative functional test suggests that increased H19 may accompany drug exposure rather than drive resistance, and the result does not extend to patients.
Science··Midday
Changing H19 did not change drug response
Researchers changed levels of H19, a long non-coding RNA, in both sensitive and resistant leukaemia cells. Raising H19 in sensitive cells and lowering it in resistant cells did not materially alter proliferation, programmed cell death or response to azacitidine. The observed increase in H19 therefore failed functional testing as a mechanism that drives drug resistance. This negative result separates a marker that changes alongside exposure from a factor that actually produces resistance.[1]
Extended drug exposure raised H19 levels
Extended azacitidine exposure increased H19 expression in two leukaemia cell models, K562 and HEL. Azacitidine is a drug used for some blood cancers that affects chemical marks on DNA. H19 rose while resistant cells maintained proliferation and showed a weaker cell-death response, initially making it a plausible resistance candidate. The unsuccessful intervention test instead indicated that the increase could accompany exposure or other resistance processes without causing them.[1]
Validation was limited to one resistant model
Researchers changed H19 function in just one resistant cell line. The findings come from cell culture and provide no direct information about drug resistance, treatment choice or clinical outcomes in people. The supported conclusion is narrower: increased H19 was not by itself a resistance mechanism in these experiments. Further models are needed to identify which other cellular processes sustain azacitidine resistance and whether H19 serves only as a marker of exposure.[1]
